W

WuXi XDC Cayman Inc
HKEX:2268

Watchlist Manager
WuXi XDC Cayman Inc
HKEX:2268
Watchlist
Price: 24.55 HKD -5.58% Market Closed
Market Cap: 29.4B HKD
Have any thoughts about
WuXi XDC Cayman Inc?
Write Note

WuXi XDC Cayman Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

WuXi XDC Cayman Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
W
WuXi XDC Cayman Inc
HKEX:2268
Gross Profit
ÂĄ559.6m
CAGR 3-Years
310%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Gross Profit
ÂĄ15.4B
CAGR 3-Years
27%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Gross Profit
ÂĄ3.8B
CAGR 3-Years
19%
CAGR 5-Years
30%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Gross Profit
ÂĄ6.6B
CAGR 3-Years
18%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Gross Profit
ÂĄ2.5B
CAGR 3-Years
8%
CAGR 5-Years
15%
CAGR 10-Years
26%
M
MGI Tech Co Ltd
SSE:688114
Gross Profit
ÂĄ1.5B
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

WuXi XDC Cayman Inc
Glance View

Market Cap
29.4B HKD
Industry
Life Sciences Tools & Services

WuXi XDC Cayman Inc is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Wuxi, Jiangsu and currently employs 1,113 full-time employees. The company went IPO on 2023-11-17. WuXi XDC Cayman Inc is a holding company primarily engaged in the provision of contract research, development and manufacturing services (CRDMO) for antibody drug conjugates (ADCs) and a wider range of bioconjugate drugs. The firm conducts its businesses through two segments. Research Services on Fee-for-service(FFS) Basis segment providing research services to its customers through FFS contracts. The Research Services on Full-time-equivalent(FTE) Basis segment providing a project team of employees dedicated to the customer's studies for a specific period of time. Based on biopharmaceuticals and small molecule drugs, the Company also provides comprehensive cross-domain services, covering the discovery, process development and good manufacturing practice (GMP) production of bioconjugated drugs, linkers and payloads. The firm conducts its business in domestic and foreign markets.

Intrinsic Value
28.63 HKD
Undervaluation 14%
Intrinsic Value
Price
W

See Also

What is WuXi XDC Cayman Inc's Gross Profit?
Gross Profit
559.6m CNY

Based on the financial report for Dec 31, 2023, WuXi XDC Cayman Inc's Gross Profit amounts to 559.6m CNY.

What is WuXi XDC Cayman Inc's Gross Profit growth rate?
Gross Profit CAGR 3Y
310%

Over the last year, the Gross Profit growth was 114%. The average annual Gross Profit growth rates for WuXi XDC Cayman Inc have been 310% over the past three years .

Back to Top